ArticleScience immunology2022
Allelic variation in class I HLA determines CD8
Abstract read
In one paragraph
Article in Science immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 77 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
77citing papers in PubMed, 1 pooled it
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
77 citing papers in PubMed, 1 synthesis or guideline pooled it.
- The association of human leucocyte antigen (HLA) alleles with COVID-19 severity: A systematic review and meta-analysis.Reviews in medical virology · 2023Pooled it
- Computational identification of antigen-specific T cell groups through generative epitope modeling.iScience · 2026Article
- T-cell receptor alpha to beta chains binding prediction.Briefings in bioinformatics · 2026Article
- Nonclassical MHC-I Molecules: Emerging Therapeutic Targets in Next-Generation Immunotherapy.MedComm · 2026Review
- Deciphering antigen-driven T cell responses through vectorized TCRdist sequence neighborhood quantification.bioRxiv : the preprint server for biology · 2026Article
- Identification of immunodominant T cell epitopes in SARS-CoV-2 spike protein in Syrian hamsters.Journal of immunology (Baltimore, Md. : 1950) · 2026Article
- Characterization of Human Leukocyte Antigen (HLA) Proteins with Integrated Immunopeptidomics and Proteomics Approach.Methods in molecular biology (Clifton, N.J.) · 2026Article
- Assessment of computational methods in predicting TCR-epitope binding recognition.Nature methods · 2026Article
- Resistance potential of the HLA-A2-restricted immunodominant SARS-CoV-2-specific CD8Nature communications · 2025Article
- Exploration of the roles of HLAs when predicting infection status by T cell receptors.Scientific reports · 2025Article
- Identification of antigen-specific functional CD8iScience · 2025Article
- A pan-disease and population-level single-cell TCRαβ repertoire reference.Cell discovery · 2025Article
- Allele-specific HLA LOH in solid tumors: distinct patterns by tumor type and potential prognostic relevance.Journal for immunotherapy of cancer · 2025Article
- Benchmarking of T cell receptor-epitope predictors with ePytope-TCR.Cell genomics · 2025Article
- Analysis of Hyperexpanded T Cell Clones in SARS-CoV-2 Vaccine-Associated Liver Injury by Spatial Proteomics and Transcriptomics.Liver international : official journal of the International Association for the Study of the Liver · 2025Article
- TCRCluster: a novel approach to T-cell receptor latent featurization and clustering using contrastive learning-guided two-stage variational autoencoders.NAR genomics and bioinformatics · 2025Article
- Differential reactivity of SARS-CoV-2 S-protein T-cell epitopes in vaccinated versus naturally infected individuals.Clinical & translational immunology · 2025Article
- LightCTL: lightweight contrastive TCR-pMHC specificity learning with context-aware prompt.Briefings in bioinformatics · 2025Article
- Age and Latent Cytomegalovirus Infection Do Not Affect the Magnitude of De Novo SARS-CoV-2-Specific CD8European journal of immunology · 2025Article
- Patterns of restricted TCR usage following SARS-CoV-2 vaccination and severe disease.Frontiers in immunology · 2025Article
17 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
35 authors.
Joshua M FrancisRepertoire Immune Medicines, Cambridge, MA, USA.ORCID 0000-0001-5727-7498
Del Leistritz-EdwardsRepertoire Immune Medicines, Cambridge, MA, USA.ORCID 0000-0002-5286-6573
Augustine DunnRepertoire Immune Medicines, Cambridge, MA, USA.ORCID 0000-0002-8683-1459
Christina TarrRepertoire Immune Medicines, Cambridge, MA, USA.
Jesse LehmanRepertoire Immune Medicines, Cambridge, MA, USA.ORCID 0000-0002-3729-2866
Conor DempseyRepertoire Immune Medicines, Cambridge, MA, USA.
Andrew HamelRepertoire Immune Medicines, Cambridge, MA, USA.
Violeta RayonRepertoire Immune Medicines, Cambridge, MA, USA.ORCID 0000-0002-2446-2395
Gang LiuRepertoire Immune Medicines, Cambridge, MA, USA.
Yuntong WangRepertoire Immune Medicines, Cambridge, MA, USA.ORCID 0000-0001-9331-2959
Marcos WilleRepertoire Immune Medicines, Cambridge, MA, USA.
Melissa DurkinRepertoire Immune Medicines, Cambridge, MA, USA.ORCID 0000-0001-6886-2203
Kane HadleyRepertoire Immune Medicines, Cambridge, MA, USA.ORCID 0000-0002-2520-155X
Aswathy SheenaRepertoire Immune Medicines, Cambridge, MA, USA.ORCID 0000-0002-7277-457X
Benjamin RoscoeRepertoire Immune Medicines, Cambridge, MA, USA.
Mark NgRepertoire Immune Medicines, Cambridge, MA, USA.ORCID 0000-0002-3289-135X
Graham RockwellRepertoire Immune Medicines, Cambridge, MA, USA.ORCID 0000-0003-2738-326X
Margaret MantoRepertoire Immune Medicines, Cambridge, MA, USA.ORCID 0000-0002-9393-179X
Elizabeth GiengerRepertoire Immune Medicines, Cambridge, MA, USA.ORCID 0000-0001-7647-1229
Joshua NickersonRepertoire Immune Medicines, Cambridge, MA, USA.ORCID 0000-0001-5125-229X
MGH COVID-19 Collection and Processing TeamMassachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Amir MoarefiRepertoire Immune Medicines, Cambridge, MA, USA.ORCID 0000-0002-3047-8262
Michael NobleRepertoire Immune Medicines, Cambridge, MA, USA.ORCID 0000-0002-6704-1793
Thomas MaliaRepertoire Immune Medicines, Cambridge, MA, USA.
Philip D BardwellRepertoire Immune Medicines, Cambridge, MA, USA.ORCID 0000-0002-3835-255X
William GordonRepertoire Immune Medicines, Cambridge, MA, USA.ORCID 0000-0003-2032-2325
Joanna SwainRepertoire Immune Medicines, Cambridge, MA, USA.ORCID 0000-0003-0818-8434
Mojca SkoberneRepertoire Immune Medicines, Cambridge, MA, USA.
Karsten SauerRepertoire Immune Medicines, Cambridge, MA, USA.
Tim HarrisRepertoire Immune Medicines, Cambridge, MA, USA.ORCID 0000-0002-5621-7861
Ananda W GoldrathDivision of Biological Sciences, Molecular Biology Section, University of California, San Diego, San Diego, CA, USA.ORCID 0000-0002-5900-508X
Alex K ShalekRepertoire Immune Medicines, Cambridge, MA, USA.ORCID 0000-0001-5670-8778
Anthony J CoyleRepertoire Immune Medicines, Cambridge, MA, USA.
Christophe BenoistDepartment of Immunology, Harvard Medical School, Boston, MA, USA.ORCID 0000-0003-1172-6555
Daniel C PregibonRepertoire Immune Medicines, Cambridge, MA, USA.ORCID 0000-0003-1084-3653
Funding
T cell maintenance: molecular mediators of T cell differentiation and survivalR37AI067545 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Ananda W Goldrath · 2022 to 2026
$3.0MTriggering germline-encoded broadly neutralizing antibody responses against influenza virusR01AI153098 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI BATISTA, FACUNDO DAMIAN, LINGWOOD, DANIEL · 2020 to 2023
$2.1MSystemic coordination of pro-inflammatory immune reactions through dendritic cell-restricted sIL6R biogenesisR01AI155447 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI LINGWOOD, DANIEL · 2021 to 2025
$2.0MNIAID NIH HHS R01 AI153098NIAID NIH HHS R01 AI155447NIAID NIH HHS R37 AI067545
Abstract
Effective presentation of antigens by human leukocyte antigen (HLA) class I molecules to CD8
Indexed as
AllelesCOVID-19Receptors, Antigen, T-Cell, alpha-betaCD8-Positive T-LymphocytesHistocompatibility Antigens Class IHumansMemory T CellsSARS-CoV-2Histocompatibility Antigens Class IReceptors, Antigen, T-Cell, alpha-beta
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.